PAEDIATRICS

Not currently approved for paediatric use.

ELDERLY

Clinical trial analysis in this limited patient population found no clinically meaningful difference in risankizumab exposure between patients 65 years of age or older and adult population.

PREGNANCY
NEW GLOBAL
GUIDELINES

For access to the full guidelines click here

Women with IBD who are pregnant or attempting conception should continue anti-IL23 therapy throughout pregnancy.13

BREASTFEEDING

Mothers with IBD currently on anti-IL 12/23 and anti-IL23 agents may breastfeed.13